Top

Archives of Gynecology and Obstetrics

Published in:

01-03-2018 | Gynecologic Oncology

Simultaneous detection of circulating and disseminated tumor cells in primary breast cancer patients following neoadjuvant chemotherapy

Authors: Vincent P. Walter, Florin-Andrei Taran, Markus Wallwiener, Markus Hahn, Sara Y. Brucker, Andreas D. Hartkopf

Published in: Archives of Gynecology and Obstetrics | Issue 3/2018

Abstract

Purpose

Pathological complete response (pCR) is a common endpoint in neoadjuvant chemotherapy (NACT) of primary breast cancer patients (PBC), but does not address the systemic prevalence of minimal residual disease. In this study, we compared pCR with the detection of circulating (CTC) and disseminated tumor cells (DTC) following NACT, as well as their impact on survival.

Methods

Patients with PBC receiving NACT and consecutive surgery were eligible for this study. CTCs were detected using the CellSearch^® system and DTCs were determined using immunocytochemistry (cytokeratin staining with the A45-B/B3 antibody). pCR was defined as ypT0/ypTis and ypN0.

Results

58 patients were included in the analysis with a median follow-up of 30 months. Of these, 5 (9%) presented with CTCs and 36 (62%) with DTCs. 16 patients (28%) achieved a pCR. No significant correlation between CTCs, DTCs and pCR and no statistically significant impact on disease free (DFS) or overall survival (OS) was apparent.

Conclusions

Both CTCs and DTCs are detectable after NACT. As we could not show a significant relationship between CTC detection, DTC detection and pCR, all three methods may provide independent information regarding treatment response. Since we were unable to show a significant impact on survival, larger prospective studies that include CTCs and DTCs are needed. These trials should include the molecular characterization of primary tumor tissue, CTCs and DTCs to determine whether these cells are independent subpopulations of malignant cell clones.

Kaufmann M, von Minckwitz G, Mamounas EP et al (2012) Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 19:1508–1516. https://doi.org/10.1245/s10434-011-2108-2 CrossRefPubMed

Thompson AM, Moulder-Thompson SL (2012) Neoadjuvant treatment of breast cancer. Ann Oncol 23:x231–x236. https://doi.org/10.1093/annonc/mds324 CrossRefPubMed

Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol 26:778–785. https://doi.org/10.1200/JCO.2007.15.0235 CrossRefPubMed

Mauri D, Pavlidis N, Ioannidis JPA (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. JNCI J Natl Cancer Inst 97:188–194. https://doi.org/10.1093/jnci/dji021 CrossRefPubMed

Von Minckwitz G, Untch M, Blohmer JU et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796–1804. https://doi.org/10.1200/JCO.2011.38.8595 CrossRef

Cortazar P, Zhang L, Untch M et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172. https://doi.org/10.1016/S0140-6736(13)62422-8 CrossRefPubMed

Braun S, Vogl FD, Naume B et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793–802. https://doi.org/10.1056/NEJMoa050434 CrossRefPubMed

Rack B, Schindlbeck C, Juckstock J et al (2014) Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. https://doi.org/10.1093/jnci/dju066 PubMedPubMedCentral

Hartkopf AD, Wallwiener M, Hahn M et al (2016) Simultaneous detection of disseminated and circulating tumor cells in primary breast cancer patients. Cancer Res Treat 48:115–124. https://doi.org/10.4143/crt.2014.287 CrossRefPubMed

10.

Janni WJ, Rack B, Terstappen LWMM et al (2016) Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer. Clin Cancer Res 22:2583–2593. https://doi.org/10.1158/1078-0432.CCR-15-1603 CrossRefPubMed

11.

Hartkopf AD, Taran FA, Wallwiener M et al (2014) Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients—results from a large single-centre analysis. Eur J Cancer 50:2550–2559. https://doi.org/10.1016/j.ejca.2014.06.025 CrossRefPubMed

12.

Lucci A, Hall CS, Lodhi AK et al (2012) Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 13:688–695. https://doi.org/10.1016/S1470-2045(12)70209-7 CrossRefPubMed

13.

Bidard F-C, Proudhon C, Pierga J-Y (2016) Circulating tumor cells in breast cancer. Mol Oncol 10:418–430. https://doi.org/10.1016/j.molonc.2016.01.001 CrossRefPubMedPubMedCentral

14.

Pierga J-Y, Bidard F-C, Mathiot C et al (2008) Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 14:7004–7010. https://doi.org/10.1158/1078-0432.CCR-08-0030 CrossRefPubMed

15.

Hall C, Karhade M, Laubacher B et al (2015) Circulating tumor cells after neoadjuvant chemotherapy in stage I–III triple-negative breast cancer. Ann Surg Oncol 22:552–558. https://doi.org/10.1245/s10434-015-4600-6 CrossRef

16.

Hartkopf AD, Taran F-A, Wallwiener M et al (2013) The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy. Breast Cancer Res 15:R94. https://doi.org/10.1186/bcr3496 CrossRefPubMedPubMedCentral

17.

Mathiesen RR, Borgen E, Renolen A et al (2012) Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Res 14:R117. https://doi.org/10.1186/bcr3242 CrossRefPubMedPubMedCentral

18.

Hall C, Krishnamurthy S, Lodhi A et al (2012) Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer. Cancer 118:342–348. https://doi.org/10.1002/cncr.26202 CrossRefPubMed

19.

Fehm T, Braun S, Muller V et al (2006) A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 107:885–892. https://doi.org/10.1002/cncr.22076 CrossRefPubMed

20.

Arbeitsgemeinschaft Gynäkologische, Onkologie E.V. (AGO) AGO-Online—Mamma. http://www.ago-online.de/de/infothek-fuer-aerzte/leitlinienempfehlungen/mamma/. Accessed 20 Sep 2016

21.

Kasimir-Bauer S, Bittner A-K, König L et al (2016) Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy. Breast Cancer Res 18:20. https://doi.org/10.1186/s13058-016-0679-3 CrossRefPubMedPubMedCentral

22.

Bidard F-C, Michiels S, Mueller V, et al (2016) IMENEO: international MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy. In: San Antonio breast cancer symposium. San Antonio, pp 538–539

23.

Kasimir-Bauer S, Reiter K, Aktas B et al (2016) Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: influence of bisphosphonate intake? Sci Rep 6:26355. https://doi.org/10.1038/srep26355 CrossRefPubMedPubMedCentral

24.

Bidard F-C, Vincent-Salomon A, Sigal-Zafrani B et al (2007) Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann Oncol 19:496–500. https://doi.org/10.1093/annonc/mdm507 CrossRef

25.

Riethdorf S, Müller V, Zhang L et al (2010) Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 16:2634–2645. https://doi.org/10.1158/1078-0432.CCR-09-2042 CrossRefPubMed

26.

Hosseini H, Obradović MMS, Hoffmann M et al (2016) Early dissemination seeds metastasis in breast cancer. Nature. https://doi.org/10.1038/nature20785 PubMedCentral

27.

Becker S, Solomayer E, Becker-Pergola G et al (2007) Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients. Breast Cancer Res Treat 106:239–243. https://doi.org/10.1007/s10549-006-9484-5 CrossRefPubMed

28.

Pantel K, Braun S, Kutter D et al (1993) Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85:1419–1424. https://doi.org/10.1093/jnci/85.17.1419 CrossRefPubMed

29.

Krawczyk N, Hartkopf A, Banys M et al (2014) Prognostic relevance of induced and spontaneous apoptosis of disseminated tumor cells in primary breast cancer patients. BMC Cancer 14:394. https://doi.org/10.1186/1471-2407-14-394 CrossRefPubMedPubMedCentral

30.

Stefanovic S, Diel I, Sinn P et al (2016) Disseminated tumor cells in the bone marrow of patients with operable primary breast cancer: prognostic impact in immunophenotypic subgroups and clinical implication for bisphosphonate treatment. Ann Surg Oncol 23:757–766. https://doi.org/10.1245/s10434-015-4895-3 CrossRefPubMed

Title: Simultaneous detection of circulating and disseminated tumor cells in primary breast cancer patients following neoadjuvant chemotherapy
Authors: Vincent P. Walter
Florin-Andrei Taran
Markus Wallwiener
Markus Hahn
Sara Y. Brucker
Andreas D. Hartkopf
Publication date: 01-03-2018
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 3/2018
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-018-4669-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Simultaneous detection of circulating and disseminated tumor cells in primary breast cancer patients following neoadjuvant chemotherapy

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

Effects of dietary advice on insulin-like growth factors among healthy newborns

Screening and treatment for short cervical length in pregnancy: a physician survey in the United States

Increased proportion of mature oocytes with sustained-release growth hormone treatment in poor responders: a prospective randomized controlled study

Hypotension due to spinal anesthesia influences fetal circulation in primary caesarean sections

Bedside risk estimation of morbidly adherent placenta using simple calculator

Correction to: Simultaneous detection of periodontal pathogens in subgingival plaque and placenta of women with hypertension in pregnancy